Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLN098
- Development stage
- Preclinical
- Lead developer
- Silence Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SLN098 is a preclinical small interfering RNA (siRNA) therapeutic being developed by Silence Therapeutics for the treatment of obesity. The drug utilizes Silence's proprietary siRNA platform to target and silence the *INHBE* (Inhibin subunit beta E) gene in the liver. Human genetic evidence indicates that individuals with loss-of-function variants in the *INHBE* gene exhibit a healthy metabolic profile, characterized by reduced abdominal fat and a decreased risk of type 2 diabetes. By specifically silencing *INHBE* mRNA, SLN098 aims to mimic this protective genetic phenotype to provide a novel approach for weight management and metabolic health improvement. As of early 2024, the program is in preclinical development, with further data expected in 2026.
- Other names
- SLN098 (INHBE)
02
Targets
INHBE (Inhibin beta E chain)
Beyond the preview
Go deeper on SLN098.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLN098.